LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 82

Search options

  1. Article: Urinary markers differentially associate with kidney inflammatory activity and chronicity measures in patients with lupus nephritis.

    Akhgar, Ahmad / Sinibaldi, Dominic / Zeng, Lingmin / Farris, Alton B / Cobb, Jason / Battle, Monica / Chain, David / Cann, Jennifer A / Illei, Gábor G / Lim, S Sam / White, Wendy I

    Lupus science & medicine

    2023  Volume 10, Issue 1

    Abstract: Objective: Lupus nephritis (LN) is diagnosed by biopsy, but longitudinal monitoring assessment methods are needed. Here, in this preliminary and hypothesis-generating study, we evaluate the potential for using urine proteomics as a non-invasive method ... ...

    Abstract Objective: Lupus nephritis (LN) is diagnosed by biopsy, but longitudinal monitoring assessment methods are needed. Here, in this preliminary and hypothesis-generating study, we evaluate the potential for using urine proteomics as a non-invasive method to monitor disease activity and damage. Urinary biomarkers were identified and used to develop two novel algorithms that were used to predict LN activity and chronicity.
    Methods: Baseline urine samples were collected for four cohorts (healthy donors (HDs, n=18), LN (n=42), SLE (n=17) or non-LN kidney disease biopsy control (n=9)), and over 1 year for patients with LN (n=42). Baseline kidney biopsies were available for the LN (n=46) and biopsy control groups (n=9). High-throughput proteomics platforms were used to identify urinary analytes ≥1.5 SD from HD means, which were subjected to stepwise, univariate and multivariate logistic regression modelling to develop predictive algorithms for National Institutes of Health Activity Index (NIH-AI)/National Institutes of Health Chronicity Index (NIH-CI) scores. Kidney biopsies were analysed for macrophage and neutrophil markers using immunohistochemistry (IHC).
    Results: In total, 112 urine analytes were identified from LN, SLE and biopsy control patients as both quantifiable and overexpressed compared with HDs. Regression analysis identified proteins associated with the NIH-AI (n=30) and NIH-CI (n=26), with four analytes common to both groups, demonstrating a difference in the mechanisms associated with NIH-AI and NIH-CI. Pathway analysis of the NIH-AI and NIH-CI analytes identified granulocyte-associated and macrophage-associated pathways, and the presence of these cells was confirmed by IHC in kidney biopsies. Four markers each for the NIH-AI and NIH-CI were identified and used in the predictive algorithms. The NIH-AI algorithm sensitivity and specificity were both 93% with a false-positive rate (FPR) of 7%. The NIH-CI algorithm sensitivity was 88%, specificity 96% and FPR 4%. The accuracy for both models was 93%.
    Conclusions: Longitudinal predictions suggested that patients with baseline NIH-AI scores of ≥8 were most sensitive to improvement over 6-12 months. Viable approaches such as this may enable the use of urine samples to monitor LN over time.
    MeSH term(s) United States ; Humans ; Lupus Nephritis/diagnosis ; Lupus Nephritis/pathology ; Kidney/metabolism ; Lupus Erythematosus, Systemic/pathology ; Biomarkers/urine ; Biopsy
    Chemical Substances Biomarkers
    Language English
    Publishing date 2023-01-27
    Publishing country England
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 2779620-6
    ISSN 2053-8790
    ISSN 2053-8790
    DOI 10.1136/lupus-2022-000747
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article: The clinical impact of neuropsychiatric manifestations in early systemic lupus erythematosus.

    Illei, Gabor G

    Nature clinical practice. Rheumatology

    2007  Volume 3, Issue 8, Page(s) 428–429

    Language English
    Publishing date 2007-08
    Publishing country United States
    Document type Comment ; Journal Article
    ZDB-ID 2228569-6
    ISSN 1745-8390 ; 1745-8382
    ISSN (online) 1745-8390
    ISSN 1745-8382
    DOI 10.1038/ncprheum0553
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article: Hematopoietic stem cell transplantation in autoimmune diseases: is the glass half full or half empty?

    Illei, Gabor G

    Arthritis and rheumatism

    2006  Volume 54, Issue 12, Page(s) 3730–3734

    MeSH term(s) Autoimmune Diseases/diagnosis ; Autoimmune Diseases/surgery ; Hematopoietic Stem Cell Transplantation ; Humans ; Prognosis ; Transplantation Conditioning ; Treatment Outcome
    Language English
    Publishing date 2006-12
    Publishing country United States
    Document type Comment ; Editorial ; Research Support, N.I.H., Intramural
    ZDB-ID 127294-9
    ISSN 1529-0131 ; 0004-3591 ; 2326-5191
    ISSN (online) 1529-0131
    ISSN 0004-3591 ; 2326-5191
    DOI 10.1002/art.22257
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: circMTND5 Participates in Renal Mitochondrial Injury and Fibrosis by Sponging MIR6812 in Lupus Nephritis.

    Luan, Junjun / Jiao, Congcong / Ma, Cong / Zhang, Yixiao / Hao, Xiangnan / Zhou, Guangyu / Fu, Jingqi / Qiu, Xingyu / Li, Hongyu / Yang, Wei / Illei, Gabor G / Kopp, Jeffrey B / Pi, Jingbo / Zhou, Hua

    Oxidative medicine and cellular longevity

    2022  Volume 2022, Page(s) 2769487

    Abstract: Recent studies have focused on nuclear-encoded circular RNAs (circRNAs) in kidney diseases, but little is known about mitochondrial circRNAs. Differentially expressed circRNAs were analyzed by RNA deep sequencing from lupus nephritis (LN) biopsies and ... ...

    Abstract Recent studies have focused on nuclear-encoded circular RNAs (circRNAs) in kidney diseases, but little is known about mitochondrial circRNAs. Differentially expressed circRNAs were analyzed by RNA deep sequencing from lupus nephritis (LN) biopsies and normal human kidneys. In LN renal biopsies, the most downregulated circRNA was circMTND5, which is encoded in the mitochondrial genome. We quantitated circMTND5 by qPCR and localized by fluorescence in situ hybridization (FISH). Mitochondrial abnormalities were identified by electron microscopy. The expression of mitochondrial genes was decreased, and the expression of profibrotic genes was increased on qPCR and immunostaining. RNA binding sites for MIR6812 and circMTND5 were predicted. MIR6812 expression was increased by FISH and qPCR. In HK-2 cells and its mitochondrial fraction, the role of circMTND5 sponging MIR6812 was assessed by their colocalization in mitochondria on FISH, RNA immunoprecipitation, and RNA pulldown coupled with luciferase reporter assay. circMTND5 knockdown upregulated MIR6812, decreased mitochondrial functional gene expression, and increased profibrotic gene expression. Overexpression of circMTND5 reversed these effects in hTGF-
    MeSH term(s) Humans ; Fibrosis ; In Situ Hybridization, Fluorescence ; Kidney/pathology ; Kidney Diseases/genetics ; Kidney Diseases/metabolism ; Lupus Nephritis/genetics ; Lupus Nephritis/metabolism ; Lupus Nephritis/pathology ; MicroRNAs/genetics ; MicroRNAs/metabolism ; Mitochondria/metabolism ; RNA, Circular/genetics
    Chemical Substances MicroRNAs ; RNA, Circular ; MT-ND5 protein, human (EC 1.6.99.3)
    Language English
    Publishing date 2022-10-11
    Publishing country United States
    Document type Journal Article
    ZDB-ID 2455981-7
    ISSN 1942-0994 ; 1942-0994
    ISSN (online) 1942-0994
    ISSN 1942-0994
    DOI 10.1155/2022/2769487
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: The MIDORA trial: a phase II, randomised, double-blind, placebo-controlled, mechanistic insight and dosage optimisation study of the efficacy and safety of dazodalibep in patients with rheumatoid arthritis.

    Kivitz, Alan / Wang, Liangwei / Alevizos, Ilias / Gunsior, Michele / Falloon, Judith / Illei, Gabor / St Clair, E William

    RMD open

    2023  Volume 9, Issue 3

    Abstract: Objectives: To evaluate the safety, efficacy and response duration of four different dosing regimens of dazodalibep (DAZ), a non-antibody biological antagonist of CD40L, in patients with rheumatoid arthritis (RA).: Methods: This double-blind study ... ...

    Abstract Objectives: To evaluate the safety, efficacy and response duration of four different dosing regimens of dazodalibep (DAZ), a non-antibody biological antagonist of CD40L, in patients with rheumatoid arthritis (RA).
    Methods: This double-blind study included adult patients with moderate-to-severe active RA with a positive test for serum rheumatoid factor and/or anticitrullinated protein antibodies, an inadequate response to methotrexate, other conventional disease-modifying antirheumatic drugs or tumour necrosis factor-α inhibitors, and no prior treatment with B-cell depleting agents. Eligible participants were randomised equally to five groups receiving intravenous infusions of DAZ or placebo. The primary endpoint was the change from baseline in the Disease Activity Score-28 with C reactive protein (DAS28-CRP) at day 113. Participants were followed through day 309.
    Results: The study randomised 78 eligible participants. The change from baseline in DAS28-CRP (least squares means±SE) at day 113 was significantly greater for all DAZ groups (-1.83±0.28 to -1.90±0.27; p<0.05) relative to PBO (-1.06±0.26); significant reductions in DAS28-CRP were also observed for all DAZ groups at day 309. The distribution of adverse events was generally balanced among DAZ and PBO groups (74% and 63%, respectively). There were four serious adverse events deemed by investigators to be unrelated to study medication.
    Conclusions: DAZ treatment for all dosage regimens significantly reduced DAS28-CRP at day 113 relative to PBO. The safety data suggest an acceptable safety and tolerability profile. Treatment effects at day 113 and the prolonged duration of responses after DAZ cessation support the use of longer dosing intervals.
    Trial registration number: NCT04163991.
    MeSH term(s) Adult ; Humans ; Antirheumatic Agents ; Arthritis, Rheumatoid/drug therapy ; Double-Blind Method ; Immunologic Factors/adverse effects ; Methotrexate ; Rheumatoid Factor
    Chemical Substances Antirheumatic Agents ; Immunologic Factors ; Methotrexate (YL5FZ2Y5U1) ; Rheumatoid Factor (9009-79-4)
    Language English
    Publishing date 2023-08-03
    Publishing country England
    Document type Clinical Trial, Phase II ; Journal Article ; Randomized Controlled Trial ; Research Support, Non-U.S. Gov't
    ZDB-ID 2812592-7
    ISSN 2056-5933 ; 2056-5933
    ISSN (online) 2056-5933
    ISSN 2056-5933
    DOI 10.1136/rmdopen-2023-003317
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: Lupus Low Disease Activity State (LLDAS) attainment discriminates responders in a systemic lupus erythematosus trial:

    Morand, Eric F / Trasieva, Teodora / Berglind, Anna / Illei, Gabor G / Tummala, Raj

    Annals of the rheumatic diseases

    2018  Volume 77, Issue 5, Page(s) 706–713

    Abstract: Objectives: In a : Methods: Patients received intravenous placebo (n=102) or anifrolumab (300 mg, n=99; 1,000 mg, n=104) Q4W plus standard of care for 48 weeks. LLDAS attainment (SLE Disease Activity Index 2000 ≤4 without major organ activity, no new ...

    Abstract Objectives: In a
    Methods: Patients received intravenous placebo (n=102) or anifrolumab (300 mg, n=99; 1,000 mg, n=104) Q4W plus standard of care for 48 weeks. LLDAS attainment (SLE Disease Activity Index 2000 ≤4 without major organ activity, no new disease activity, Physician's Global Assessment ≤1, prednisolone ≤7.5 mg/d and standard immunosuppressant dosage tolerance) was assessed. Associations with endpoints and LLDAS attainment differences between treatments were explored.
    Results: LLDAS attainment at Week 52 was associated with SLE Responder Index 4 (SRI[4]) and British Isles Lupus Assessment Group-based Composite Lupus Assessment (BICLA) (74/85[87%] and 62/84[74%] were also SRI[4] and BICLA responders, respectively; both nominal p<0.001). Only 74/159 (47%) of SRI(4) and 62/121 (51%) of BICLA responders reached LLDAS.Anifrolumab-treated patients achieved earlier LLDAS, and more spent at least half their observed time in LLDAS (OR vs. placebo; 300 mg: 3.04, 95% CI 1.34 to 6.92, nominal p=0.008; 1,000 mg: 2.17, 95% CI 0.93 to 5.03, nominal p=0.072) vs placebo-treated patients. At Week 52, 17/102 (17%), 39/99 (39%) and 29/104 (28%) of patients on placebo, anifrolumab 300 and 1,000 mg, respectively, attained LLDAS (OR vs. placebo; 300 mg: 3.41, 95% CI 1.73 to 6.76, p<0.001; 1,000 mg: 2.03, 95% CI 1.01 to 4.07, nominal p=0.046).
    Conclusions: LLDAS attainment represents a clinically meaningful SLE outcome measure, and anifrolumab is associated with more patients who met LLDAS criteria versus placebo. These data support LLDAS as an SLE RCT endpoint.
    Trial registration number: NCT1438489; Post-results.
    MeSH term(s) Adult ; Antibodies, Monoclonal/therapeutic use ; Antibodies, Monoclonal, Humanized ; Female ; Humans ; Immunosuppressive Agents/therapeutic use ; Lupus Erythematosus, Systemic/drug therapy ; Lupus Erythematosus, Systemic/pathology ; Male ; Middle Aged ; Minimal Clinically Important Difference ; Prednisolone/therapeutic use ; Severity of Illness Index ; Treatment Outcome
    Chemical Substances Antibodies, Monoclonal ; Antibodies, Monoclonal, Humanized ; Immunosuppressive Agents ; anifrolumab (38RL9AE51Q) ; Prednisolone (9PHQ9Y1OLM)
    Language English
    Publishing date 2018-02-02
    Publishing country England
    Document type Clinical Trial, Phase II ; Journal Article ; Randomized Controlled Trial ; Research Support, Non-U.S. Gov't
    ZDB-ID 7090-7
    ISSN 1468-2060 ; 0003-4967
    ISSN (online) 1468-2060
    ISSN 0003-4967
    DOI 10.1136/annrheumdis-2017-212504
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: Long-term follow-up after lymphodepleting autologous haematopoietic cell transplantation for treatment-resistant systemic lupus erythematosus.

    Goklemez, Sencer / Hasni, Sarfaraz / Hakim, Frances T / Muraro, Paolo A / Pirsl, Filip / Rose, Jeremy / Memon, Sarfraz / Fowler, Daniel F / Steinberg, Seth M / Baker, Eva H / Panch, Sandya R / Gress, Ronald / Illei, Gabor G / Lipsky, Peter E / Pavletic, Steven Z

    Rheumatology (Oxford, England)

    2022  Volume 61, Issue 8, Page(s) 3317–3328

    Abstract: ... mobilization with CYC, G-CSF and rituximab was followed by collection of CD34+ positively selected cells ...

    Abstract Objective: Autologous haematopoietic cell transplantation (AHSCT) improves immunologic dysfunction in patients with SLE. However, the curative potential of this therapy remains uncertain. This study reports outcomes in SLE patients receiving a lymphodepleting, reduced intensity regimen for AHSCT in SLE.
    Methods: Eight patients with SLE refractory to treatment, including i.v. cyclophosphamide (CYC), were enrolled. Five had LN and three CNS involvement as primary indications for transplant. Haematopoietic cell mobilization with CYC, G-CSF and rituximab was followed by collection of CD34+ positively selected cells. The conditioning regimen consisted of concurrent administration of CYC, fludarabine and rituximab. All immunosuppressive medications were discontinued at the start of mobilization and CS were rapidly tapered after the transplant.
    Results: Five of eight patients achieved a complete response, including a decline in the SLEDAI to zero, which was sustained in four patients for a median of 165 months (range 138-191). One patient achieved a partial response, which was followed by relapse at month 18. Two patients with nephritis and underlying comorbidities in most organs had early deaths from infection and multiorgan failure. AHSCT resulted in profound lymphodepletion, followed by expansion of Treg cells and repopulation of naive T and B cells. Patients with a complete response showed a sustained suppression of the SLE-associated IFN-induced gene signature, marked depletion of memory and plasmablast B cells and resultant sustained elimination of anti-dsDNA antibody.
    Conclusion: Durable clinical and serologic remissions with suppression in the IFN gene signature can be achieved in refractory SLE following lymphodepleting AHSCT.
    Trial registration: ClinicalTrials.gov, https://clinicaltrials.gov, NCT00076752.
    MeSH term(s) Antibodies, Antinuclear ; Cyclophosphamide/therapeutic use ; Follow-Up Studies ; Hematopoietic Stem Cell Transplantation/methods ; Humans ; Lupus Erythematosus, Systemic ; Rituximab/therapeutic use ; Transplantation, Autologous ; Treatment Outcome
    Chemical Substances Antibodies, Antinuclear ; anti-dsDNA autoantibody ; Rituximab (4F4X42SYQ6) ; Cyclophosphamide (8N3DW7272P)
    Language English
    Publishing date 2022-01-06
    Publishing country England
    Document type Journal Article ; Research Support, N.I.H., Intramural
    ZDB-ID 1464822-2
    ISSN 1462-0332 ; 1462-0324
    ISSN (online) 1462-0332
    ISSN 1462-0324
    DOI 10.1093/rheumatology/keab877
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: Can quantified salivary gland scintigraphy results aid diagnosis of patients with sicca symptoms?

    Roescher, Nienke / Illei, Gabor G

    Nature clinical practice. Rheumatology

    2008  Volume 4, Issue 4, Page(s) 178–179

    Language English
    Publishing date 2008-04
    Publishing country United States
    Document type Comment ; Journal Article
    ZDB-ID 2228569-6
    ISSN 1745-8390 ; 1745-8382
    ISSN (online) 1745-8390
    ISSN 1745-8382
    DOI 10.1038/ncprheum0759
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article ; Online: MicroRNAs as biomarkers in rheumatic diseases.

    Alevizos, Ilias / Illei, Gabor G

    Nature reviews. Rheumatology

    2010  Volume 6, Issue 7, Page(s) 391–398

    Abstract: MicroRNAs (miRNAs) are endogenous, noncoding, single-stranded RNAs of 19-25 nucleotides in length. They regulate gene expression and are important in a wide range of physiological and pathological processes. MiRNAs are attractive as potential biomarkers ... ...

    Abstract MicroRNAs (miRNAs) are endogenous, noncoding, single-stranded RNAs of 19-25 nucleotides in length. They regulate gene expression and are important in a wide range of physiological and pathological processes. MiRNAs are attractive as potential biomarkers because their expression pattern is reflective of underlying pathophysiologic processes and they are specific to various disease states. Moreover, miRNAs can be detected in a variety of sources, including tissue, blood and body fluids; they are reasonably stable and appear to be resistant to differences in sample handling, which increases their appeal as practical biomarkers. The clinical utility of miRNAs as diagnostic or prognostic biomarkers has been demonstrated in various malignancies and a few nonmalignant diseases. There is accumulating evidence that miRNAs have an important role in systemic rheumatic diseases and that various diseases or different stages of the same disease are associated with distinct miRNA expression profiles. Preliminary data suggest that miRNAs are promising as candidate biomarkers of diagnosis, prognosis, disease activity and severity in autoimmune diseases. MiRNAs identified as potential biomarkers in pilot studies should be validated in larger studies designed specifically for biomarker validation.
    MeSH term(s) Animals ; Biomarkers/metabolism ; Humans ; MicroRNAs/metabolism ; Rheumatic Diseases/metabolism
    Chemical Substances Biomarkers ; MicroRNAs
    Language English
    Publishing date 2010-06-01
    Publishing country United States
    Document type Journal Article ; Review
    ZDB-ID 2491532-4
    ISSN 1759-4804 ; 1759-4790
    ISSN (online) 1759-4804
    ISSN 1759-4790
    DOI 10.1038/nrrheum.2010.81
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article ; Online: MicroRNAs in Sjögren's syndrome as a prototypic autoimmune disease.

    Alevizos, Ilias / Illei, Gabor G

    Autoimmunity reviews

    2010  Volume 9, Issue 9, Page(s) 618–621

    Abstract: MicroRNAs are endogenous non-coding RNAs, approximately 22 nucleotides in length. They regulate gene expression and are important in a wide range of physiological and pathological processes. MicroRNA expression is tightly regulated during hematopoiesis ... ...

    Abstract MicroRNAs are endogenous non-coding RNAs, approximately 22 nucleotides in length. They regulate gene expression and are important in a wide range of physiological and pathological processes. MicroRNA expression is tightly regulated during hematopoiesis and lymphoid cell differentiation and disruption of the entire microRNA network or selected microRNAs may lead to dysregulated immune responses. Abnormalities in microRNA expression related to inflammatory cytokines, Th-17 and regulatory T cells as well as B cells have been described in several autoimmune diseases. Sjogren's syndrome is characterized by features of systemic autoimmunity and chronic inflammation and dysfunction in exocrine organs. Its clinical characteristics along with the relatively easy access to the target tissue and its product makes Sjögren's syndrome appealing to study many aspects of microRNAs in a systemic autoimmune disease, such as their potential as diagnostic or prognostic biomarkers and their role in pathogenesis of autoimmunity, inflammation or organ dysfunction. Encouraging preliminary data from pilot studies in Sjogren's syndrome demonstrate the potential of microRNAs as putative diagnostic and prognostic biomarker candidates which should be tested in larger more definite studies. Combining the comparison of microRNA expression profiles between various clinical subsets of Sjögren's syndrome with bioinformatic modeling tools may predict formerly unsuspected pathways which may contribute to the disease process and lead to the generation of testable novel hypothesis of pathogenesis.
    MeSH term(s) Arthritis, Rheumatoid/genetics ; Autoimmune Diseases/genetics ; Autoimmune Diseases/immunology ; Humans ; Lupus Erythematosus, Systemic/genetics ; MicroRNAs/genetics ; MicroRNAs/physiology ; Multiple Sclerosis/genetics ; Sjogren's Syndrome/diagnosis ; Sjogren's Syndrome/genetics ; Sjogren's Syndrome/immunology
    Chemical Substances MicroRNAs
    Language English
    Publishing date 2010-05-10
    Publishing country Netherlands
    Document type Journal Article ; Review
    ZDB-ID 2144145-5
    ISSN 1873-0183 ; 1568-9972
    ISSN (online) 1873-0183
    ISSN 1568-9972
    DOI 10.1016/j.autrev.2010.05.009
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top